Wells Fargo & Company Celularity Inc Transaction History

Wells Fargo & Company

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.17 - $0.33 $8 - $17	52 Added 0.48%	10,852 $2,000
Q3 2023 Nov 13, 2023	BUY	$0.22 - $0.56 $32 - $81	146 Added 1.37%	10,800 $2,000
Q2 2023 Aug 15, 2023	SELL	$0.42 - $0.81 $4,869 - $9,391	-11,594 Reduced 52.11%	10,654 $5,000
Q1 2023 May 12, 2023	BUY	$0.56 - $1.15 $6,809 - $13,983	12,160 Added 120.54%	22,248 $13,000
Q4 2022 Feb 13, 2023	SELL	$1.08 - $2.35 $1,179 - $2,566	-1,092 Reduced 9.77%	10,088 $13,000
Q3 2022 Nov 14, 2022	BUY	$0.43 - $4.31 $4,662 - $46,737	10,844 Added 3227.38%	11,180 $26,000
Q2 2022 Aug 12, 2022	BUY	$2.81 - $12.91 $944 - $4,337	336 New	336 $1,000
Q1 2022 May 16, 2022	BUY	$3.81 - $9.79 $0 - $0	0 New	0 $0

23.6M

Ticker CELU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,424,000
Market Cap $319M
Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-de...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.